---
layout: post
title: "八大券商主题策略：回调即买入机会！重申看好新冠防治产业链 三大逻辑力挺中药股"
date: 2022-04-14 11:44:50 +0800
categories: emnews
tags: 东财滚动新闻
---
> 国信证券表示，医药行业一季度的业绩延续了新冠疫情的主线，我们预计疫苗、新冠检测业务将维持高景气度的增长；同时，CXO行业也将受益于全球产业链转移而继续高增长，新冠药物相关的CDMO业务也将为相关公司带来较大的业绩增量。

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" data-code="BK1040|90|1" data-code2="BK1040|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1040&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1040_0" data-code="K BK1040|90|1" data-code2="K BK1040|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" data-code="BK1041|90|1" data-code2="BK1041|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1041&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1041_0" data-code="K BK1041|90|1" data-code2="K BK1041|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>每日主题策略讨论，<span id="stock_0.300059"><a href="http://quote.eastmoney.com/unify/r/0.300059" class="keytip" data-code="0,300059">东方财富</a></span><span id="quote_0.300059"></span>网汇总八大<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>观点，揭秘行业现状，观察行情走势，提前为您把脉A股。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25036694776047018283_w544h461.jpg" width="544" emheight="461" orginial_src="https://dfscdn.dfcfw.com/download/D25036694776047018283_w544h461_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong><span id="stock_1.600369"><a href="http://quote.eastmoney.com/unify/r/1.600369" class="keytip" data-code="1,600369">西南证券</a></span><span id="quote_1.600369"></span>：<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>消费品具备消费属性！持续看好<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>消费品三大逻辑</strong></p><p>广东省中成药集采降幅好于预期，<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>消费品具备消费属性，以院外市场为主，相对医保免疫，持续看好中药消费品三大逻辑：1)提价：近几年部分上游中药材持续提价，成本向下游传导，带动终端产品提价，有望增厚<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>，重点关注<span id="stock_1.600436"><a href="http://quote.eastmoney.com/unify/r/1.600436" class="keytip" data-code="1,600436">片仔癀</a></span><span id="quote_1.600436"></span>、<span id="stock_1.600085"><a href="http://quote.eastmoney.com/unify/r/1.600085" class="keytip" data-code="1,600085">同仁堂</a></span><span id="quote_1.600085"></span>、<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="stock_1.603896"><a href="http://quote.eastmoney.com/unify/r/1.603896" class="keytip" data-code="1,603896">寿仙谷</a></span><span id="quote_1.603896"></span>、<span id="stock_0.300049"><a href="http://quote.eastmoney.com/unify/r/0.300049" class="keytip" data-code="0,300049">福瑞股份</a></span><span id="quote_0.300049"></span>、<span id="stock_1.600993"><a href="http://quote.eastmoney.com/unify/r/1.600993" class="keytip" data-code="1,600993">马应龙</a></span><span id="quote_1.600993"></span>、<span id="stock_0.000915"><a href="http://quote.eastmoney.com/unify/r/0.000915" class="keytip" data-code="0,000915">华特达因</a></span><span id="quote_0.000915"></span>、<span id="stock_1.600976"><a href="http://quote.eastmoney.com/unify/r/1.600976" class="keytip" data-code="1,600976">健民集团</a></span><span id="quote_1.600976"></span>等。2)国企混改：中药行业国企混改以及<span id="Info.3286"><a href="http://data.eastmoney.com/gdfx/" class="infokey">股东</a></span>层面的变动加速落地，业绩有望释放，重点关注<span id="stock_0.000538"><a href="http://quote.eastmoney.com/unify/r/0.000538" class="keytip" data-code="0,000538">云南白药</a></span><span id="quote_0.000538"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600129" class="em_stock_key_common" data-code="1,600129">太极集团</span>、<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>等；3)库存处于低位：部分企业渠道库存清理进入尾声，进入新一轮铺货周期。</p><p>此外，还看好中药创新药、中药基药独家品种、中药配方颗粒、中药材质量控制、中医<span id="bk_90.BK0727"><a href="http://quote.eastmoney.com/unify/r/90.BK0727" class="keytip" data-code="90,BK0727">医疗服务</a></span><span id="bkquote_90.BK0727"></span>等。中药创新药：2021 年开始，我国中药创新药研发成果进入逐步兑现阶段，有望成为新增长点，建议关注<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>等出厂发货逐步恢复，业绩迎来恢复，重点关注<span web="1" href="http://quote.eastmoney.com/unify/r/1.600129" class="em_stock_key_common" data-code="1,600129">太极集团</span>、<span id="stock_0.000423"><a href="http://quote.eastmoney.com/unify/r/0.000423" class="keytip" data-code="0,000423">东阿阿胶</a></span><span id="quote_0.000423"></span>等。</p><p><strong>首创<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>：回调即买入机会 </strong><strong>重申看好新冠治疗药物产业链</strong></p><p>回调即买入机会，重申看好新冠治疗药物产业链。全球每天新冠疫情新发病例仍维持100万例以上高位，疫情防治任重道远。全球新冠疫情高位运行的启示：防应优先于治，新冠疫苗防重症、降低死亡率作用显著，新冠病毒长期与人类共存，治疗药物是必需。</p><p>建议关注：第一、小分子特效药：重申小分子特效药贯穿全年投资机会，回调即买入机会，建议关注上游中间体、原料药(<span id="stock_0.300261"><a href="http://quote.eastmoney.com/unify/r/0.300261" class="keytip" data-code="0,300261">雅本化学</a></span><span id="quote_0.300261"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>(森萱医药)和<span id="stock_1.603538"><a href="http://quote.eastmoney.com/unify/r/1.603538" class="keytip" data-code="1,603538">美诺华</a></span><span id="quote_1.603538"></span>)及国内临床进度较快且技术路线相对成熟的国产药物(<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、开拓药业)。</p><p>第二、中药：我们更看好受众人群更广的高普适性品种，建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>。</p><p>第三、疫苗：我们看好疫苗建议关注非灭活技术路线，建议关注<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺</a></span><span id="quote_1.688185"></span>、<span id="stock_1.600196"><a href="http://quote.eastmoney.com/unify/r/1.600196" class="keytip" data-code="1,600196">复星医药</a></span><span id="quote_1.600196"></span>、<span id="stock_0.300142"><a href="http://quote.eastmoney.com/unify/r/0.300142" class="keytip" data-code="0,300142">沃森生物</a></span><span id="quote_0.300142"></span>、<span id="Info.116.01093"><a href="http://quote.eastmoney.com/unify/r/116.01093" class="keytip" data-code="116,01093">石药集团</a></span>。</p><p><strong><span id="stock_0.002736"><a href="http://quote.eastmoney.com/unify/r/0.002736" class="keytip" data-code="0,002736">国信证券</a></span><span id="quote_0.002736"></span>：关注疫情相关的检测、小分子药物、中药、疫苗等板块</strong></p><p>医药行业一季度的业绩延续了新冠疫情的主线，我们预计疫苗、新冠检测业务将维持高景气度的增长；同时，CXO行业也将受益于全球产业链转移而继续高增长，新冠药物相关的CDMO业务也将为相关公司带来较大的业绩增量。</p><p>中医药十四五规划颁布，新冠疫情重塑中药认知。首次以国务院办公厅名义发布中医药五年规划，各项指标的设置充分体现了国家振兴中医药发展的宏伟目标。中医药行业正处于一个振兴发展的阶段，中医药作为我国特色药品和服务种类，一直受到国家政策支持，特别是2021年以来，国务院、医保局等多个国家高层级部门发布多项实际政策鼓励中医药发展，明确了中医药作为我国传统特色，国家各部门从上到下鼓励支持中药发展的态度。同时，新冠疫情重塑中药认知，传承与发扬中医药成为主调。</p><p>关注新冠主线以及估值合理的优质个股。新冠疫情仍为医药板块的最大主线，建议关注疫情相关的检测、小分子药物、中药、疫苗等板块。另外，部分优质个股前期回调幅度较大，估值已经相当具有吸引力，建议积极布局。4月投资组合为A股：<span id="stock_1.600276"><a href="http://quote.eastmoney.com/unify/r/1.600276" class="keytip" data-code="1,600276">恒瑞医药</a></span><span id="quote_1.600276"></span>、<span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>、<span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>、<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002603" class="em_stock_key_common" data-code="0,002603">以岭药业</span>、<span id="stock_1.688617"><a href="http://quote.eastmoney.com/unify/r/1.688617" class="keytip" data-code="1,688617">惠泰医疗</a></span><span id="quote_1.688617"></span>；H股：<span id="Info.116.01066"><a href="http://quote.eastmoney.com/unify/r/116.01066" class="keytip" data-code="116,01066">威高股份</a></span>、<span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>、康诺亚、先瑞达医疗。</p><p><strong><span id="stock_1.600109"><a href="http://quote.eastmoney.com/unify/r/1.600109" class="keytip" data-code="1,600109">国金证券</a></span><span id="quote_1.600109"></span>：建议关注业绩高成长兑现和疫情防控双主线</strong></p><p>继续看好CXO 板块的年报一季报行情。CXO 板块4 月份将继续迎来年报/一季报的集中披露，行业高景气，板块业绩和订单等情况持续向好，预计市场情绪将进一步回暖，估值有进一步提升修复的空间。</p><p>继续看好产业链上游原料药板块和医药上游供应链：①原料药板块产业升级(CDMO)+产业延展双路径成长，预计2022 年API 板块盈利能力将持续得到提升。②看好十四五期间供应链方面的投资机遇(产业升级+国产替代)，包括装备设备、科学仪器、科研配套上游试剂耗材、医药工业上游耗材和原辅料包材等细分领域，特别是短期疫情防控上游供应链。</p><p>投资建议来看，建议关注业绩高成长兑现和疫情防控双主线，疫情防控主要包括检测消杀、疫苗和特效药及其研发产业链、上游供应链等，其中重点关注疫苗、特效药(中外)及其研发产业链及中药抗疫方向。建议关注：<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>、<span id="stock_0.300347"><a href="http://quote.eastmoney.com/unify/r/0.300347" class="keytip" data-code="0,300347">泰格医药</a></span><span id="quote_0.300347"></span>、<span id="stock_1.688105"><a href="http://quote.eastmoney.com/unify/r/1.688105" class="keytip" data-code="1,688105">诺唯赞</a></span><span id="quote_1.688105"></span>、以岭药业等。</p><p><strong><span id="stock_1.601456"><a href="http://quote.eastmoney.com/unify/r/1.601456" class="keytip" data-code="1,601456">国联证券</a></span><span id="quote_1.601456"></span>：关注新冠相关产业链及一季度具有确定性成长的公司</strong></p><p>关注新冠相关产业链及一季度具有确定性成长的公司。国内疫情防控仍将是市场关注热点，投资较为活跃，我们建议重点关注国产新冠药物研发进展及新冠检测产业链相关公司。受疫情影响，疫情后建设值得思考，建议持续关注医疗新基建的进度，有望增加优质医疗资源供给，成为行业核心驱动。此外，一季度业绩将陆续公布，疫情或对相关公司带来业绩干扰，建议关注一季度有确定性成长的公司。疫苗及CXO 相关产业链仍是具有高成长的板块，建议持续关注。</p><p><strong><span id="stock_1.600030"><a href="http://quote.eastmoney.com/unify/r/1.600030" class="keytip" data-code="1,600030">中信证券</a></span><span id="quote_1.600030"></span>：看好集采常态化下中医药公司的长期发展潜力 </strong><strong>建议从五大维度选择标的</strong></p><p>整体来看，本次广东省中医药集采降价幅度会较为温和，符合预期。在人口老龄化和消费升级下具有长期增长逻辑。我们看好集采常态化下中医药公司的长期发展潜力，建议从五大维度去选择标的：①具备极强护城河、产品品牌壁垒高的龙头企业，例如<span web="1" href="http://quote.eastmoney.com/unify/r/0.000538" class="em_stock_key_common" data-code="0,000538">云南白药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600436" class="em_stock_key_common" data-code="1,600436">片仔癀</span>等企业；②业绩增长的持续性与估值相匹配：受益于配方颗粒新国标改革后放量的<span web="1" href="http://quote.eastmoney.com/unify/r/0.000999" class="em_stock_key_common" data-code="0,000999">华润三九</span>、<span id="Info.116.00570"><a href="http://quote.eastmoney.com/unify/r/116.00570" class="keytip" data-code="116,00570">中国中药</a></span>(H)、<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>；主营产品具备定价权、叠加涨价逻辑的<span id="stock_1.600285"><a href="http://quote.eastmoney.com/unify/r/1.600285" class="keytip" data-code="1,600285">羚锐制药</a></span><span id="quote_1.600285"></span>、太极集团、<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span>；③管理层改善逻辑：建议关注<span web="1" href="http://quote.eastmoney.com/unify/r/1.600085" class="em_stock_key_common" data-code="1,600085">同仁堂</span>、<span id="stock_1.600771"><a href="http://quote.eastmoney.com/unify/r/1.600771" class="keytip" data-code="1,600771">广誉远</a></span><span id="quote_1.600771"></span>等；④中药创新药增量逻辑：以岭药业、<span id="stock_1.600557"><a href="http://quote.eastmoney.com/unify/r/1.600557" class="keytip" data-code="1,600557">康缘药业</a></span><span id="quote_1.600557"></span>；⑤中医服务提供商：建议关注<span id="Info.116.02273"><a href="http://quote.eastmoney.com/unify/r/116.02273" class="keytip" data-code="116,02273">固生堂</a></span>，新中医诊疗龙头，OMO 模式全国布局持续推进，关注<span id="stock_0.000705"><a href="http://quote.eastmoney.com/unify/r/0.000705" class="keytip" data-code="0,000705">浙江震元</a></span><span id="quote_0.000705"></span>。</p><p><strong><span id="stock_1.601377"><a href="http://quote.eastmoney.com/unify/r/1.601377" class="keytip" data-code="1,601377">兴业证券</a></span><span id="quote_1.601377"></span>：相比其他行业比较优势突出 </strong><strong>建议积极配置医药板块</strong></p><p>新冠疫苗和药物研发进展频出，展望未来新冠疫情影响将有望边际缩小，医药的投资主线逐步回归于企业的“非新冠”主营业务，医药板块中的复苏机会将逐步显现：消费医疗及产业链的相关标的：例如择期手术、可选消费等，如<span id="stock_0.300015"><a href="http://quote.eastmoney.com/unify/r/0.300015" class="keytip" data-code="0,300015">爱尔眼科</a></span><span id="quote_0.300015"></span>、<span id="stock_1.688050"><a href="http://quote.eastmoney.com/unify/r/1.688050" class="keytip" data-code="1,688050">爱博医疗</a></span><span id="quote_1.688050"></span>、<span id="stock_1.600763"><a href="http://quote.eastmoney.com/unify/r/1.600763" class="keytip" data-code="1,600763">通策医疗</a></span><span id="quote_1.600763"></span>、<span id="stock_0.000963"><a href="http://quote.eastmoney.com/unify/r/0.000963" class="keytip" data-code="0,000963">华东医药</a></span><span id="quote_0.000963"></span>等。</p><p>医药的波动，本质是宏观经济周期与行业政策的叠加产物。当下医药板块从短周期维度来看，恰恰进入有望获得超额收益的投资时钟内，在疫情防疫需求下政府在对医药板块加大投入，医药收入有望有增量，而经济周期又处于下行周期。我们认为医药板块在经历持续调整后，当下迎来买入良机，估值底、仓位底、政策底均已现，且医药业绩持续性强，相比其他行业比较优势突出，建议积极配置医药板块。</p><p>投资建议来看，<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>：全球临床前CRO 龙头企业，行业地位突出；<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>：业务稳健增长，产业链地位持续提升，估值具备性价比；<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>：<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>龙头企业，研发销售能力突出，估值合理；<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>：HPV 疫苗与IVD 双轮驱动公司高增长；<span web="1" href="http://quote.eastmoney.com/unify/r/0.000963" class="em_stock_key_common" data-code="0,000963">华东医药</span>：基本面边际改善，制药板块集采压力逐步释放，管线内新增多款创新药产品，工业微生物板块及医美板块快速增长拉动业绩。</p><p><strong>东莞<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>：临近财报披露高峰期 </strong><strong>关注业绩有望超预期的医疗细分板块和标的</strong></p><p>近期，我国疫情多点散发，疫情防控正处在关键时期，关注相关受益标的。临近财报披露高峰期，关注业绩有望超预期的细分板块和标的。可关注景气度保持向好、业绩有望超预期的CXO公司<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300347" class="em_stock_key_common" data-code="0,300347">泰格医药</span>、<span id="stock_0.300759"><a href="http://quote.eastmoney.com/unify/r/0.300759" class="keytip" data-code="0,300759">康龙化成</a></span><span id="quote_0.300759"></span>、<span id="stock_1.603127"><a href="http://quote.eastmoney.com/unify/r/1.603127" class="keytip" data-code="1,603127">昭衍新药</a></span><span id="quote_1.603127"></span>、<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、九州药业、<span id="stock_1.688202"><a href="http://quote.eastmoney.com/unify/r/1.688202" class="keytip" data-code="1,688202">美迪西</a></span><span id="quote_1.688202"></span>等；有望受益需求上升的新冠抗原检测试剂相关企业<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688298" class="em_stock_key_common" data-code="1,688298">东方生物</span>、<span id="stock_1.688075"><a href="http://quote.eastmoney.com/unify/r/1.688075" class="keytip" data-code="1,688075">安旭生物</a></span><span id="quote_1.688075"></span>、<span id="stock_1.688068"><a href="http://quote.eastmoney.com/unify/r/1.688068" class="keytip" data-code="1,688068">热景生物</a></span><span id="quote_1.688068"></span>、<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>、<span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span>等；关注研发能力强、非新冠产品有望实现快增的疫苗企业<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300142" class="em_stock_key_common" data-code="0,300142">沃森生物</span>等。估值相对合理的<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1041" class="em_stock_key_common" data-code="90,BK1041">医疗器械</span>龙头<span web="1" href="http://quote.eastmoney.com/unify/r/0.300760" class="em_stock_key_common" data-code="0,300760">迈瑞医疗</span>、医美龙头<span id="stock_0.300896"><a href="http://quote.eastmoney.com/unify/r/0.300896" class="keytip" data-code="0,300896">爱美客</a></span><span id="quote_0.300896"></span>、OK镜龙头<span id="stock_0.300595"><a href="http://quote.eastmoney.com/unify/r/0.300595" class="keytip" data-code="0,300595">欧普康视</a></span><span id="quote_0.300595"></span>、眼科器械龙头<span web="1" href="http://quote.eastmoney.com/unify/r/1.688050" class="em_stock_key_common" data-code="1,688050">爱博医疗</span>等；中期有望受益老龄化、内生增长动力较强的连锁医疗龙头<span web="1" href="http://quote.eastmoney.com/unify/r/0.300015" class="em_stock_key_common" data-code="0,300015">爱尔眼科</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600763" class="em_stock_key_common" data-code="1,600763">通策医疗</span>；估值有所回落、业绩有望向好的品牌中药<span web="1" href="http://quote.eastmoney.com/unify/r/1.600436" class="em_stock_key_common" data-code="1,600436">片仔癀</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000538" class="em_stock_key_common" data-code="0,000538">云南白药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600085" class="em_stock_key_common" data-code="1,600085">同仁堂</span>等。</p><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/0.300059" class="em_stock_key_common" data-code="0,300059">东方财富</span>研究中心）</p>

<http://stock.eastmoney.com/news/1405,202204142343260765.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)